EUVIMEDEUVIMED entdecken
Crossref

Clinical utility of Circulating Long Non-Coding RNAs in indeterminate thyroid nodules

Susmita Dutta, Soham Tarafdar, Nitai P Bhattacharyya, Pradip Mukhopadhyay, Kaushik Pandit, Sujoy Ghosh iD

Endocrine-Related Cancer · 03.11.2026

DOI: 10.1530/erc-26-0375 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, online erschienen am 03.11.2026. Verfasst von Susmita Dutta und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Indeterminate cytology results (Bethesda categories III and IV) from fine-needle aspiration (FNA) create challenges in clinical decision-making. This study evaluated the expression and diagnostic utility of selected long non-coding RNAs (lncRNAs) in cell-free plasma from patients with indeterminate thyroid nodules.

Design

Prospective, single-center study.

Methods

Nine candidate long non-coding RNA were selected from a curated disease database. A total of 126 individuals with solitary thyroid nodules were enrolled. RNA was extracted from plasma, FNA, and tissue samples and expression levels were measured using quantitative real-time PCR. In the discovery cohort, patients with benign and malignant nodules confirmed by histopathology, were used to determine optimal cut-off values through receiver operating characteristic analysis. Spearman correlation analyses were performed to assess concordance between plasma and FNA/tissue expression. In the validation phase, significantly altered markers were applied to indeterminate nodules to assess diagnostic performance.

Results

In the discovery cohort, PVT1, MALAT1, and BANCR were significantly upregulated in malignant compared with benign nodules (P < 0.0001). Significant positive correlations were observed between plasma and FNA expression for PVT1 (r = 0.7095), MALAT1 (r = 0.5487), and BANCR (r = 0.6792), and between plasma and tissue expression for PVT1 (r = 0.7673), MALAT1 (r = 0.5284), and BANCR (r = 0.6864) (P < 0.0001). In the Bethesda III/IV validation cohort, only PVT1 retained diagnostic utility, with 76% sensitivity, 87.5% specificity, 85% positive predictive value, and 80% negative predictive value, whereas MALAT1 and BANCR did not demonstrate significant diagnostic performance.

Conclusions

Circulating PVT1 expression in plasma may serve as a useful non-invasive biomarker for distinguishing benign from malignant indeterminate thyroid nodules.

Schlagwörter

Stichwörter der Autor:innen

Circulating long non-coding RNAs (lncRNAs)Indeterminate cytologyLiquid biopsy and Differentiated thyroid cancerPVT1

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.
  • Senior Resident, Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.
  • Professor, Senior Research Advisor, Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.
  • Professor, Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.
  • Hony. Scientific Officer. Department of Endocrinology and Metabolism, IPGME&R , Kolkata, India.

ORCID-Profile: Sujoy Ghosh

Zitieren

APA

Dutta, S., Tarafdar, S., Bhattacharyya, N. P., Mukhopadhyay, P., Pandit, K., & Ghosh, S. (2026). Clinical utility of Circulating Long Non-Coding RNAs in indeterminate thyroid nodules. Endocrine-Related Cancer. https://doi.org/10.1530/erc-26-0375

Vancouver

Dutta S, Tarafdar S, Bhattacharyya NP, Mukhopadhyay P, Pandit K, Ghosh S. Clinical utility of Circulating Long Non-Coding RNAs in indeterminate thyroid nodules. Endocrine-Related Cancer. 2026. doi:10.1530/erc-26-0375

BibTeX
@article{Dutta2026,
  author = {Dutta, Susmita and Tarafdar, Soham and Bhattacharyya, Nitai P and Mukhopadhyay, Pradip and Pandit, Kaushik and Ghosh, Sujoy},
  title = {Clinical utility of Circulating Long Non-Coding RNAs in indeterminate thyroid nodules},
  journal = {Endocrine-Related Cancer},
  year = {2026},
  doi = {10.1530/erc-26-0375}
}
Kostenlos starten →